School of Pharmacy and Pharmacology, College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia.
School of Pharmacy and Pharmacology, College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia.
Redox Biol. 2021 Jan;38:101812. doi: 10.1016/j.redox.2020.101812. Epub 2020 Nov 25.
Idebenone is a well described drug that was initially developed against dementia. The current literature widely portrays this molecule as a potent antioxidant and CoQ analogue. While numerous papers seem to support this view, a closer look indicates that the pharmacokinetics of idebenone do not support these claims. A major discrepancy between achievable tissue levels, especially in target tissues such as the brain, and doses required to show the proposed effects, significantly questions our current understanding. This review explains how this has happened and highlights the discrepancies in the current literature. More importantly, based on some recent discoveries, a new framework is presented that can explain the mode of action of this molecule and can align formerly contradictory results. Finally, this new appreciation of the molecular activities of idebenone provides a rational approach to test idebenone in novel indications that might have not been considered previously for this drug.
依达拉奉是一种描述详尽的药物,最初是为治疗痴呆而开发的。目前的文献广泛将这种分子描述为一种有效的抗氧化剂和 CoQ 类似物。虽然许多论文似乎支持这种观点,但仔细观察表明,依达拉奉的药代动力学并不支持这些说法。依达拉奉在实现组织水平(尤其是大脑等靶组织)方面存在显著差异,特别是与显示预期效果所需的剂量之间存在显著差异,这使得我们目前对其的理解受到了质疑。本综述解释了这种情况是如何发生的,并强调了当前文献中的差异。更重要的是,基于一些最近的发现,提出了一个新的框架,可以解释这种分子的作用模式,并可以将以前相互矛盾的结果统一起来。最后,对依达拉奉分子活性的新认识为该药物在以前可能未被考虑过的新适应症中进行测试提供了合理的方法。